TFM
RXRX icon

TFC Financial Management’s Recursion Pharmaceuticals RXRX Stock Holding History

TFC Financial Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1
Closed -$6 – 1072
2025
Q1 		$6 Buy
+1
New +$7 ﹤0.01% 958

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

TFC Financial Management's RXRX Position: Q2 2025 in Review

TFC Financial Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 1 share — an estimated $6 sold.

TFC Financial Management first reported a position in RXRX in Q1 2025 and held it in 1 quarter. The position peaked at $6 in Q1 2025. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • TFC Financial Management reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • TFC Financial Management sold 1 Recursion Pharmaceuticals share in Q2 2025, an estimated $6.
  • TFC Financial Management first reported a position in Recursion Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • TFC Financial Management's Recursion Pharmaceuticals position peaked at $6 in Q1 2025.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on TFC Financial Management's 13F filing for Q2 2025, filed 29 Jul 2025.